These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1901613)

  • 21. Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya.
    Elghoul MT; Joshi RM; Rizghalla T
    Trop Geogr Med; 1989 Oct; 41(4):304-8. PubMed ID: 2517554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Studies on the problems of resistance to antituberculous drugs. II--2. Clinically significant critical concentration of streptomycin, isoniazid, kanamycin and ethambutol].
    Baba H
    Kekkaku; 1994 Jun; 69(6):397-407. PubMed ID: 8041058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
    Lu T; Drlica K
    J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of rifampicin on the intra- and extracellularly located Mycobacterium tuberculosis].
    Pavlov EP; Tushov EG; Kotliarov LM
    Probl Tuberk; 1974; (12):64-7. PubMed ID: 4216898
    [No Abstract]   [Full Text] [Related]  

  • 26. [Activities of rifampicin, capreomycin, viomycin or kanamycin against Mycobacterium tuberculosis isolated from tuberculosis patients].
    Endo K
    Jpn J Antibiot; 1970 Aug; 23(4):387-9. PubMed ID: 4321638
    [No Abstract]   [Full Text] [Related]  

  • 27. [Sensitivity to rifampicin and ethambutol of mycobacteria resistant to isoniazid or streptomycin].
    Golychevskaja VI
    G Ital Chemioter; 1972; 19(2):20-2. PubMed ID: 4199029
    [No Abstract]   [Full Text] [Related]  

  • 28. [Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
    Matsumiya T; Freerksen E; Rosenfeld M
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):14-29. PubMed ID: 4320557
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental and clinical study test of capreomycin].
    Kozlova NV; Dzhumaev B; Stepanian ES; Kaminskaia GO
    Antibiotiki; 1976 Jul; 21(7):650-4. PubMed ID: 60080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cross resistance of Mycobacterium tuberculosis to streptomycin, kanamycin and viomycin].
    Makarevich NM; Mkrtchian SV; Afanas'eva IuP
    Antibiotiki; 1970 Apr; 15(4):345-51. PubMed ID: 4321321
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-tuberculous initial drug resistance of Mycobacterium tuberculosis in Kenya: a ten-year review.
    Githui WA; Kwamanga D; Chakaya JM; Karimi FG; Waiyaki PG
    East Afr Med J; 1993 Oct; 70(10):609-12. PubMed ID: 8187653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania.
    Matee M; Mfinanga S; Holm-Hansen C
    APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Resistance of Mycobacterium tuberculosis strains to antimycobacterial preparations].
    Iavors'ka HV; Puhachevs'ka LP
    Mikrobiol Z; 2006; 68(5):44-51. PubMed ID: 17388119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-tuberculosis drug resistance and therapeutic dead end].
    Veziris N; Robert J
    Med Sci (Paris); 2010 Nov; 26(11):976-80. PubMed ID: 21106180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cross-resistance relationships of antituberculosis drugs in Mycobacterium avium complex].
    Tsukamura M
    Kekkaku; 1989 Jan; 64(1):1-5. PubMed ID: 2709652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-resistant strains of Mycobacterium tuberculosis isolated in Russia.
    Stepanshina VN; Panfertsev EA; Korobova OV; Shemyakin IG; Stepanshin YG; Medvedeva IM; Dorozhkova IR
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):149-52. PubMed ID: 10091881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Basic evaluation for new antimicrobial susceptibility testing of Mycobacterium tuberculosis by bioluminescence assay of mycobacterial ATP].
    Yamazaki T; Sato N; Okazawa Y; Tanno K
    Rinsho Byori; 1998 Aug; 46(8):834-40. PubMed ID: 9760838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Toungoussova S; Caugant DA; Sandven P; Mariandyshev AO; Bjune G
    Int J Tuberc Lung Dis; 2002 May; 6(5):406-14. PubMed ID: 12019916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic characterization of the mechanism by which certain strains of Escherichia coli survive in high kanamycin concentrations.
    Cisneros Benavides ME
    Rev Latinoam Microbiol; 1992; 34(1):53-60. PubMed ID: 1345305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.